2-[1-[6-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyridazin-3-yl]indol-3-yl]-N-benzylacetamide
C33H32N6O3 — CID 117085125
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[1-[6-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyridazin-3-yl]indol-3-yl]-N-benzylacetamide
2-[1-[6-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyridazin-3-yl]indol-3-yl]-N-benzylacetamide (PubChem CID 117085125) has the molecular formula C33H32N6O3 and a molecular weight of 560.66 g/mol. Its IUPAC name is 2-[1-[6-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyridazin-3-yl]indol-3-yl]-N-benzylacetamide.
Molecular Properties
| Compound Name | 2-[1-[6-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyridazin-3-yl]indol-3-yl]-N-benzylacetamide |
|---|---|
| PubChem CID | 117085125 |
| Molecular Formula | C33H32N6O3 |
| Molecular Weight | 560.66 g/mol |
| Exact Mass | 560.25 |
| IUPAC Name | 2-[1-[6-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyridazin-3-yl]indol-3-yl]-N-benzylacetamide |
| SMILES | O=C(Cc1cn(-c2ccc(N3CCN(Cc4ccc5c(c4)OCO5)CC3)nn2)c2ccccc12)NCc1ccccc1 |
| InChI | InChI=1S/C33H32N6O3/c40-33(34-20-24-6-2-1-3-7-24)19-26-22-39(28-9-5-4-8-27(26)28)32-13-12-31(35-36-32)38-16-14-37(15-17-38)21-25-10-11-29-30(18-25)42-23-41-29/h1-13,18,22H,14-17,19-21,23H2,(H,34,40) |
| InChIKey | KXUUNFSUUGXCIV-UHFFFAOYSA-N |
| XLogP | 4.33 |
| TPSA | 84.75 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 42 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 560.66 |
| LogP ≤ 5 | 4.33 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 117085125 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.